Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

New Joint Care Products In Brief

This article was originally published in The Tan Sheet

Executive Summary

Nordic Naturals ProEFA Xtra: Nordic Naturals Physician Exclusive Division releases ProEFA Xtra, which the firm says "delivers more functional fatty acids per capsule than any other product" and is "designed to effectively support joint flexibility and immune health." A two-capsule serving delivers 850 mg eicosapentaenoic acid and 220 mg docosahexaenoic acid, as well as 257 mg gamma linolenic acid, the Watsonville, Calif.-based firm says Nov. 14. These essential fatty acids (EFAs) are "delivered in triglyceride form, the form in which EFAs occur naturally in the food and the human body," Nordic Naturals adds. The company also says one serving of Pro EFA Xtra "meets the American Heart Association recommendation of 1 gram of EPA and DHA for individuals concerned with heart health"...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS099986

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel